GLAUCOMA 1, OPEN ANGLE, D (Disorder)NCT07765147
Evaluating iCare COMPASS as a Visual Field Diagnostic Tool
A study testing VISUAL FIELD TESTING in people with GLAUCOMA 1, OPEN ANGLE, D (Disorder), run by Indiana University at 1 site in United States.
Trial summary
this study seeks to compare the Humphrey Visual Field Analyzer and iCare COMPASS for both clinical accuracy and operational advantages. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- GLAUCOMA 1, OPEN ANGLE, D (Disorder)
- What is being tested?
- VISUAL FIELD TESTING
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 28 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Feb 2025to 16 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- All consenting patients who arrive for glaucoma management appointments for objective(s) 2.1.1, 2.2.2
- Patient groups arriving for glaucoma management that will be targeted for enrollment include: glaucoma suspect patients, those with cataracts, optic atrophy, macular degeneration, macular pathology, and vascular diseases of the retina
Who cannot join
- Those who are unwilling or unable to provide consent
- Those for which English is not their first language
Trial locations and contacts
1 site in 1 country.
United States1 site
Eugene and Marilyn Glick Eye Institute
Indianapolis, Indiana, 46202
About this study
this study seeks to compare the Humphrey Visual Field Analyzer and iCare COMPASS for both clinical accuracy and operational advantages.
- Conditions
- GLAUCOMA 1, OPEN ANGLE, D (Disorder)
- Being tested
- VISUAL FIELD TESTING
- Keywords
- GLAUCOMA
- Medical subject headings
- Glaucoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VISUAL FIELD TESTINGDiagnostic test
This study will be a crossover study. Patients who express interest in taking part in the study will be evaluated using Humphrey SITA-faster, which is the current standard of care for visual perimetry, and the iCare COMPASS in the same visit. Participants will be assigned to one of two groups of alternating testing order with the Humphrey Visual Field Analyzer vs the iCare COMPASS and vice versa. The mean deviation, pattern standard deviation, mean deviation cluster, and fixation plot results will be compared. For analysis, participants will be grouped according to the inclusion criteria.
| Study group | Role | What they receive |
|---|---|---|
| HUMPHREY SITA FASTER VS ICARE COMPASS | Active comparator | SUBJECTS WILL BE RANDOMIZED TO TESTING ON THE HUMPHREY SITA FASTER VISUAL FIELD FIRST, THEN WILL TEST ON THE ICARE COMPASS VISUAL FIELD MACHINE Receives: Diagnostic Test: VISUAL FIELD TESTING |
| ICARE COMPASS VS HUMPHREY SITA FASTER | Active comparator | SUBJECTS WILL BE RANDOMIZED TO TEST FIRST ON THE ICARE COMPASS VISUAL FIELD MACHINE, THEN WILL TEST ON THE HUMPHREY SITA FASTER VISUAL FIELD MACHINE Receives: Diagnostic Test: VISUAL FIELD TESTING |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual Fields will be assessed via the current standard of care Humphrey SITA-Faster when available. The mean deviation, pattern standard deviation, mean deviation cluster, and fixation plot obtained will be compared with the same measures on the iCare
Testing will be performed with either one or two encounters with the patient or as determined by the patients' clinician.
Measured: within 1-3 months post visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2026
- Study start7 Feb 2025
- Primary completion16 Jan 2026
- Study completion16 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GLAUCOMA 1, OPEN ANGLE, D (Disorder)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 28 participants (actual)
Sponsor and investigators
- Lead sponsor
- Indiana University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Masood Mohammadi, Indiana University
- Investigators
- MASOOD MOHAMMADI, MD, Principal investigator, Indiana University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07765147
- Sponsor's protocol ID
- 22747
- Status last verified
- Aug 2026
- First submitted
- 11 Aug 2026
- Last updated
- 14 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating iCare COMPASS as a Visual Field Diagnostic Tool
- ClinicalTrials.gov ID
- NCT07765147
- Acronym / sponsor ID
- 22747
- Conditions
- GLAUCOMA 1, OPEN ANGLE, D (Disorder)
- Keywords
- GLAUCOMA
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 28 participants (actual)
- Lead sponsor
- Indiana UniversityUniversity, hospital or other
- Study start
- 7 Feb 2025 (actual)
- Primary completion
- 16 Jan 2026 (actual)
- Study completion
- 16 Jan 2026 (actual)
- First posted
- 14 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
this study seeks to compare the Humphrey Visual Field Analyzer and iCare COMPASS for both clinical accuracy and operational advantages.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| HUMPHREY SITA FASTER VS ICARE COMPASS | Active comparator | Diagnostic Test: VISUAL FIELD TESTINGSUBJECTS WILL BE RANDOMIZED TO TESTING ON THE HUMPHREY SITA FASTER VISUAL FIELD FIRST, THEN WILL TEST ON THE ICARE COMPASS VISUAL FIELD MACHINE |
| ICARE COMPASS VS HUMPHREY SITA FASTER | Active comparator | Diagnostic Test: VISUAL FIELD TESTINGSUBJECTS WILL BE RANDOMIZED TO TEST FIRST ON THE ICARE COMPASS VISUAL FIELD MACHINE, THEN WILL TEST ON THE HUMPHREY SITA FASTER VISUAL FIELD MACHINE |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- All consenting patients who arrive for glaucoma management appointments for objective(s) 2.1.1, 2.2.2
- Patient groups arriving for glaucoma management that will be targeted for enrollment include: glaucoma suspect patients, those with cataracts, optic atrophy, macular degeneration, macular pathology, and vascular diseases of the retina
Key exclusion criteria (2 listed)
- Those who are unwilling or unable to provide consent
- Those for which English is not their first language
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VISUAL FIELD TESTINGThis study will be a crossover study. Patients who express interest in taking part in the study will be evaluated using Humphrey SITA-faster, which is the current standard of care for visual perimetry, and the iCare COMPASS in the same visit. Participants will be assigned to one of two groups of alternating testing order with the Humphrey Visual Field Analyzer vs the iCare COMPASS and vice versa. The mean deviation, pattern standard deviation, mean deviation cluster, and fixation plot results will be compared. For analysis, participants will be grouped according to the inclusion criteria. | Diagnostic test | HUMPHREY SITA FASTER VS ICARE COMPASS, ICARE COMPASS VS HUMPHREY SITA FASTER |
Primary outcome
Visual Fields will be assessed via the current standard of care Humphrey SITA-Faster when available. The mean deviation, pattern standard deviation, mean deviation cluster, and fixation plot obtained will be compared with the same measures on the iCare
Time frame: within 1-3 months post visit
Testing will be performed with either one or two encounters with the patient or as determined by the patients' clinician.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Enrolling by invitation
Direct vs. Conventional SLT in Open-Angle Glaucoma: A RCT
GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Not yet recruiting
Effect of Late Ripcord Removal From Glaucoma Drainage Device
GLAUCOMA 1, OPEN ANGLE, D (Disorder), Glaucoma
RecruitingObservational study
Long-Term Clinical Results of Ab-Interno Trabeculotomy in Glaucoma Management
Glaucoma, Glaucoma Patient
Recruiting
Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShunt
GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Recruiting
Preserflo MicroShunt Versus Trabeculectomy
GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
MASOOD MOHAMMADI, MD principal investigator
Indiana University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing VISUAL FIELD TESTING in people with GLAUCOMA 1, OPEN ANGLE, D (Disorder), run by Indiana University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual Fields will be assessed via the current standard of care Humphrey SITA-Faster when available. The mean deviation, pattern standard deviation, mean deviation cluster, and fixation plot obtained will be compared with the same measures on the iCare (time frame: within 1-3 months post visit). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.